Related Experiment Videos
Trimetrexate in relapsed T-cell lymphoma with skin involvement
1Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. a.sarris@hygeia.gr
Summary
Trimetrexate (TMTX) shows activity in relapsed T-cell lymphoma, offering a new option for patients resistant to methotrexate. This study found a 45% overall response rate with manageable side effects.
Area of Science:
- Oncology
- Pharmacology
- Dermatology
Background:
- Methotrexate (MTX) is effective for lymphomas but resistance can develop.
- Resistance to MTX is often due to transport or polyglutamylation mutations.
- Trimetrexate (TMTX) bypasses these resistance mechanisms.
Purpose of the Study:
- To investigate the activity of trimetrexate (TMTX) in patients with relapsed T-cell lymphoma.
- To evaluate TMTX in patients with resistance to methotrexate.
- To assess the safety and efficacy of TMTX in this patient population.
Main Methods:
- Eligible patients had relapsed T-cell lymphoma involving the skin.
- Patients received intravenous TMTX (200 mg/m(2)) every 14 days.
- Response was assessed, and responders received up to 12 doses.
Main Results:
- An overall response rate of 45% was observed (1 complete, 8 partial responses).
- Two of five patients previously treated with MTX responded to TMTX.
- Adverse events included mucositis (4%), infection (3%), and neutropenic fever (6%).
Conclusions:
- Trimetrexate (TMTX) demonstrates activity in relapsed T-cell lymphoma.
- TMTX has an acceptable toxicity profile in this patient group.
- Further investigation of TMTX for T-cell lymphoma is warranted.